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Low serum HDL-cholesterol (HDL-C) is a major risk factor for coronary artery disease. We performed targeted genotyping of a 12.4 Mb
linked region on 16q to test for association with low HDL-C by using a regional-tag SNP strategy. We identiﬁed one SNP, rs2548861, in
the WW-domain-containing oxidoreductase (WWOX) gene with region-wide signiﬁcance for low HDL-C in dyslipidemic families of
Mexican and European descent and in low-HDL-C cases and controls of European descent (p ¼ 6.9 3 107). We extended our investi-
gation to the population level by using two independent unascertained population-based Finnish cohorts, the cross-sectional METSIM
cohort of 4,463 males and the prospective Young Finns cohort of 2,265 subjects. The combined analysis provided p ¼ 4 3 104 to
2 3 105. Importantly, in the prospective cohort, we observed a signiﬁcant longitudinal association of rs2548861 with HDL-C levels
obtained at four different time points over 21 years (p ¼ 0.003), and the T risk allele explained 1.5% of the variance in HDL-C levels.
The rs2548861 resides in a highly conserved region in intron 8 ofWWOX. Results from our in vitro reporter assay and electrophoretic
mobility-shift assay demonstrate that this region functions as a cis-regulatory element whose associated rs2548861 SNP has a speciﬁc
allelic effect and that the region forms an allele-speciﬁc DNA-nuclear-factor complex. In conclusion, analyses of 9,798 subjects show
signiﬁcant association between HDL-C and a WWOX variant with an allele-speciﬁc cis-regulatory function.Introduction
A low level of serum HDL-C is an independent risk factor
for coronary artery disease (CAD [MIM 607339]).1 Approx-
imately half of the variance observed in HDL-C levels is
attributable to genetic factors; heritability estimates are
40%–60%.2,3 Low HDL-C is also a trait of a common dysli-
pidemia, familial combined hyperlipidemia (FCHL [MIM
144250]).1 We previously reported a linkage of the low
HDL-C trait to chromosome 16q23-q24 in the combined
analysis of genome-wide scans of Finnish and Dutch
FCHL families.4 Linkage of HDL-C to this same region
has also been observed in several additional studies, in-
cluding a study of Finnish low-HDL-C families,5 Mexican
Americans of the San Antonio Family Heart Study,6 the Fra-
mingham Heart Study7 and a study of French Canadian
low-HDL families,8 suggesting that this region harbors
one or more genes that regulate serum HDL-C levels.The antiatherogenic properties of HDL-C are well estab-
lished and include reverse cholesterol transport (RCT), as
well as antithrombotic, proﬁbrinolytic, antioxidant, and
anti-inﬂammatory properties.9 Mutations in the gene for
apolipoprotein A-I (APOA1 [MIM 107680), the most
abundant apolipoprotein of HDL particles, as well as
genes of the RCT pathway, including ATP-binding cas-
sette, sub-family A member 1 (ABCA1 [MIM 600046), lec-
ithin-cholesterol acyltransferase (LCAT [MIM 606967]),
and cholesteryl ester transport protein (CETP [MIM
118470]), have been shown to underlie Mendelian forms
of familial hyperalphalipoproteinemia (MIM 143470) and
hypoalphalipoproteinemia (FHA [MIM 604091), includ-
ing ﬁsh-eye disease (FED [MIM 136120]).10 The LCAT
and CETP genes are located 10.1 Mb and 21.1 Mb centro-
meric to the region within one LOD of the linkage peak
observed on chromosome 16q in the Finnish and Dutch
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Genome-wide association studies (GWAS) of predomi-
nantly type 2 diabetes (T2DM [MIM 125853]) cases and
controls were recently analyzed for lipid traits, including
HDL-C.11,12 These studies identiﬁed seven loci and also
conﬁrmed several genes previously known to be involved
in lipid metabolism.11,12 The types of genes identiﬁed in
a GWAS naturally reﬂect the ascertainment and pheno-
typic characteristics of the stage 1 samples. Because these
studies were mostly based on type 2 diabetes as the disease
of interest in stage 1, it is likely that some additional dysli-
pidemia-speciﬁc variants and genes will be identiﬁed in ac-
tual hyperlipidemic study samples. Moreover, the fact that
all of the variants identiﬁed in the meta-analyses of these
three studies together accounted for 5%–8% of the varia-
tion for the investigated lipid traits12 demonstrates that
the SNPs identiﬁed by the GWAS approach account for
a small fraction of the total genetic contribution. To iden-
tify additional genes and pathways that account for the
unexplained variance, the importance of less signiﬁcant
GWAS signals can be further evaluated with alternative
strategies that incorporate multiple lines of evidence,
including association studies of linked regions, functional
studies, and extension to the general population.
In the current study, we followed up on a region for
HDL-C on chromosome 16q23-q24 that has been consis-
tently replicated for HDL-C in numerous independent
linkage studies.4–8 We performed targeted genotyping of
tag SNPs in the 12.4 Mb LOD –1 region of linkage to test
for association in stage 1, and we followed up on poten-
tially positive signals in stage 2. Our two-stage study design
utilizing European-descended dyslipidemic families and
European-descended HDL-C cases and controls identiﬁed
one region-wide signiﬁcant SNP, rs2548861, in the WW
domain-containing oxidoreductase (WWOX [MIM
605131]) gene for HDL-C. Next, we examined the popula-
tion effect of rs2548861 in two independent unascertained
population-based study samples: a Finnish population-
based cohort of males and a Finnish population-based
prospective cohort. Altogether, the variant was analyzed
in 9,798 individuals. We also show functional evidence
of an allelic effect of rs2548861 in WWOX by using an
in vitro luciferase reporter assay and a comparative electro-
phoretic mobility-shift assay (EMSA).
Material and Methods
Study Participants
All participants gave written informed consent, and the institu-
tional review board of each site approved the study protocol
according to the Declaration of Helsinki principles.
Stage 1 and 2 Study Samples
The Finnish dyslipidemic families comprised of 60 FCHL and 39
low HDL-C families, were collected and phenotyped as previously
described.4,5 For the stage 1 analysis, we selected the 33 Finnish
FCHL and 17 low-HDL families that had a positive LOD score
(LOD > 0) for microsatellites in the 16q23-q24 region on the basisThe Ameof our previous genome-wide linkage analysis,4 and this resulted
in a total of 50 Finnish dyslipidemic families (322 genotyped indi-
viduals). The rs2548861 SNP was subsequently genotyped and
analyzed in all available participants of the 60 Finnish FCHL fam-
ilies (719 genotyped individuals).
Stage 2 study samples consisted of European-descended dyslipi-
demic families, comprised of Dutch FCHL and French Canadian
low-HDL-C families and low-HDL-C cases and controls of Euro-
pean descent. The 31 Dutch FCHL families were collected at
the Lipid Clinic of the Utrecht Academic University Hospital
and in Maastricht, the Netherlands, as previously described.4,13
The 24 Dutch FCHL families (144 genotyped individuals) that
had a positive linkage score to 16q23-q24 in our previous study4
were selected for the stage 2 analysis. The SNP rs2548861 was
subsequently genotyped and analyzed in all available participants
of the 31 Dutch FCHL families (546 individuals available for gen-
otyping). The 28 French Canadian low-HDL-C families (467 gen-
otyped individuals) were collected at the Cardiovascular Genetics
Laboratory, McGill University Health Center, Royal Victoria Hos-
pital in Montreal, as previously described.8 The Finnish age- and
sex-speciﬁc population tenth percentiles of HDL-C were used for
classifying all families of stage 1 and 2 analyses for the qualitative
HDL-C trait.4 The European-descended HDL-C case-control study
sample consists of 252 cases and 223 controls from the Clinique
de Pre´vention Secondaire (CPS) cohort, collected at the Preven-
tive Cardiology/Lipid Clinic at the McGill University Health Cen-
ter, Royal Victoria Hospital in Montreal, Canada14 and from the
University of California San Francisco (UCSF) Genomic Resource
in Arteriosclerosis (GRA) and collected at the UCSF,15 as previ-
ously described. Cases were deﬁned as having serum HDL-C
levels below the age- and sex-speciﬁc tenth percentile, and
controls had HDL-C levels above the age- and sex-speciﬁc 25th
percentile based on the Lipid Research Clinics Population Studies
Data Book.16
Mexican FCHL Families
Mexican FCHL families consist of 55 families (759 genotyped indi-
viduals) recruited at the Instituto Nacional de Ciencias Me´dicas y
Nutricio´n Salvador Zubira´n in Mexico City; the inclusion and ex-
clusion criteria used were as described previously.17 The Mexican
age- and sex-speciﬁc tenth percentiles for HDL-C were used for
classifying the HDL-C affection status.18 We estimated the power
of this study sample with 44 low-HDL-C affected subjects
(%10th age-sex population percentile) to be 30% by using the
PBAT software package.19 Therefore, we included these Mexican
FCHL families in the overall combined analysis rather than analyz-
ing them alone.
Finnish METSIM Cohort
The METSIM (metabolic syndrome in men) cohort consists
of 4,917 subjects (4,463 genotyped subjects) of the ongoing
METSIM Study comprised of males, age 50–70 years, randomly
selected from the population of Kuopio in Eastern Finland (popu-
lation 95,000).20 Recruitment, data collection, and phenotypic
determinations were performed at the University of Kuopio. All
participants underwent an evaluation of their disease history,
drug treatment, and cardiovascular risk factors. A fasting blood
sample was taken from all participants and tested for an extensive
panel of lipid, glucose, and other metabolic traits. Serum HDL-C
levels were measured by the enzymatic colorimetric method
(Konelab 20XTi Clinical Chemistry Analyzer, Vantaa, Finland).rican Journal of Human Genetics 83, 180–192, August 8, 2008 181
The Cardiovascular Risk in Young Finns Cohort
The Young Finns cohort is a Finnish longitudinal population
study sample on the evolution of cardiovascular risk factors from
childhood to adulthood.21 The ﬁrst cross-sectional survey was
conducted in 1980 in ﬁve Finnish university cities and their rural
surroundings and included 3,596 participants who were in the age
groups of 3, 6, 9, 12, 15, and 18 years and were randomly chosen
from the national population register; equal ratios of males and
females were selected in each age group. Between 1980 and
1992, these cohorts were re-examined in 3–6 year intervals. In
the latest follow-up in 2001, a total of 2,283 participants (of which
DNA is available from 2,265 participants) were examined for
numerous study variables, including serum lipoproteins, glucose,
insulin, obesity indices, blood pressure, life-style factors, smoking
status, alcohol use and general health status.
SNP Selection
To select the most informative and nonredundant SNPs for the
ﬁrst-stage genotyping, we utilized a tag SNP strategy in the 12.5
Mb linked region by using the HapMap pre-Phase I data.22 Tag
SNPs were selected for the CETP and LCAT genes, including a
10 Kb region upstream of each gene. We used the LDSelect pro-
gram23 to select 1,349 tag SNPs with minor allele frequency
(MAF) > 0.1 and an r2 threshold of 0.85. In addition, 63 nonsy-
nonymous SNPs were selected from genes within the region for
a total of 1,412 SNPs that were genotyped in the ﬁrst stage.
In the second stage, we selected 15 SNPs within or near the A-T
binding factor 1 (ATBF1 [MIM 104155]), contactin-associated pro-
tein-like 4 (CNTNAP4 [MIM 610518]), ADAM metallopeptidase
with thrombospondin type 1 (ADAMTS18 [MIM 607512]),
WWOX, cadherin 13 (CDH13 [MIM 601364]) and in the inter-
genic region between v-maf musculoaponeurotic ﬁbrosarcoma
oncogene (MAF [MIM 177075]) and the dynein light chain road-
block-type 2 (DYNLRB2 [MIM 607168]) genes that provided
evidence of association with p% 0.01, as well as ten SNPs within
these genes with p < 0.05, resulting in a total of 25 SNPs selected
for stage 2.
Genotyping
The stage 1 genotyping of 1,412 SNPs was performed with the
Illumina Goldengate custom panel (Illumina Inc.) at the Southern
California Genotyping Consortium. We obtained a 97% success
rate for the SNPs; there were 49 failed SNPs, 98% of the subjects
were successfully genotyped, and six subjects were excluded
from analysis. For the remaining SNPs, a genotyping call rate
greater than 98% was obtained. Forty-two SNPs that were non-
polymorphic and three SNPs with Hardy-Weinberg equilibrium
(HWE) p value < 0.001 were excluded from the analysis, resulting
in 1318 SNPs that were analyzed. Genotyping of the 25 second-
stage replication SNPs was performed by deCODEwith a deCODE/
Nanogen customized SNP platform (deCODE, Reykjavik, Iceland),
and a genotyping call rate greater than 90% was obtained for all
SNPs. The rs2548861 SNP was genotyped in the METSIM and
Young Finns cohorts with the TaqMan Allelic Discrimination
Assays (Applied Biosystems, Foster City, California). In the Mexi-
can FCHL families, rs2548861 was genotyped with the Pyrose-
quencing technique on the PSQ HS96A platform at the UCLA
Genotyping and Sequencing Core Facility (GenoSeq) with a 94%
genotyping call rate. The rs2548861 was in HWE (p > 0.5) in all
population samples analyzed. The Pedcheck program was used
for detecting Mendelian errors in the families.24182 The American Journal of Human Genetics 83, 180–192, AugusResequencing
The exons and exon-intron boundaries of the three refseq validated
isoforms of theWWOX genewere resequenced in 16 Finnish dyslipi-
demic probands from the families that provided the strongest signal
for both linkagewithmicrosatellitemarkers in the 16q23-q24 region
andassociationwith rs2548861 in theﬁrst-stageanalysis. Inaddition,
a 525 bp region surrounding rs2548861was resequenced in 48 Finn-
ish probands and24Dutchprobands. The sampleswere ampliﬁedby
PCR for the Applied Biosystems 3730 Capillary DNA Analyzer
(Applied Biosystems). PCR primers were designed with the Primer3
program.25 Sequence contigs were assembled with the use of the
Sequencher software (GeneCodes Corporation, Ann Arbor, MI).
Statistical Analysis
Because 16q is a known region of linkage for HDL-C, association
analysis of the stage 1 and2 familieswas performedwith the empir-
ical variance option –e of the family-based association test (FBAT)
software26 that tests for association in the presence of linkage.
The stage 1 and 2 dyslipidemic families were ascertained through
aproband and at least one affectedﬁrst-degree relativewith dyslipi-
demia. We tested HDL-C as a binary trait because the variance of
HDL-C is reduced for effective quantitative analysis in the stage
1 and 2 dyslipidemic families, which have on average ﬁve low-
HDL-C affected individuals per family. We tested the additive
model in stage 1 because several studies have shown that it is robust
for detecting association even when the true genetic model is not
additive.27–29 In the joint analysis of stage 1 and 2 families, we
tested both the additive and dominant models and present the
model that provided themore signiﬁcant result (Table 1). The reces-
sivemodelwasnot testedbecauseour family studydidnothave suf-
ﬁcientpower todetect susceptibility alleleswith a recessivemodeof
inheritance. The case-control subjects of European descent were
analyzed by logistic regression analysis for the additive and domi-
nant models also, as implemented in the PLINK v1.01 software.30
We estimated the marginal effect size of rs2548861 on the basis of
the logistic regression coefﬁcient (b) and the sample average pro-
portion (P), according to the equation MES ¼ b 3 P (1  P). We
also performed a combined analysis of the family-based and case-
control studies (n ¼ 1,408) by using the Z method to combine the
statistics for the 25 SNPs.We combined test statistics from the fam-
ily-based and the case-control studies by using equal weights to
calculate the corresponding combined p value.12,31 In addition,
for the SNP rs2548861, all available subjects of the stage 1 and 2
families, the case-control subjects, and 55 Mexican FCHL families
were included in an overall combined analysis (n ¼ 3,070). To cor-
rect for the multiple tests performed, we adjusted for 1,318 SNPs
tested in stage 1 and 25 SNPs tested for the additive and dominant
models, resulting in Bonferroni correction for 1,368 independent
tests in the combined analysis of stage 1 and 2 and for 1,369 tests
in theoverall combinedanalysis.Wealso estimated this pvalue em-
pirically by combining the statistics from 50,000 randompermuta-
tions of the case-control status and 50,000 random gene-dropping
procedures in the families. We used the Mendel software for the
gene-dropping procedure.32 To examine the evidence for linkage
in families associated with the risk allele of rs2548861, we per-
formed subset linkage analyses by using an approach similar to
one described previously.33 We divided the families based on
whether the family contributed positively to the Z score statistic
of FBAT.26 The location score analysis of the SimWalk2 program34
v.2.91 was used for performing the parametric multipoint analysis
for each subset and for the combined samples.t 8, 2008
Table 1. Association Results of Stage 1 and 2 Analyses for the Low-HDL-C Trait
SNP
Nearest
Gene Allele Frequencya
Stage 1
Families
Modelb
Stage 1 and 2
Family-Based
Joint Analysisc
Stage 2
Cases and Controls
Stage 1 and 2
Combined Analysis
Z P Z P Frequencyd OR (95% CI)e Z P Z P
rs1837020 ATBF1 A 0.19 2.0 0.05 A 1.4 ns 0.19/0.16 0.9 (0.6–1.2) 0.9 ns 1.6 ns
rs2157786 ATBF1 A 0.75 2.6 0.01 A 3.0 0.003 0.67/0.67 1.0 (0.7–1.3) 0.2 ns 2.2 0.03
rs8056528 ATBF1 C 0.25 2.9 0.004 D 2.9 0.003 0.30/0.33 1.1 (0.8–1.7) 0.8 ns 1.5 ns
rs160952 CNTNAP4 T 0.29 2.8 0.005 A 2.2 0.03 0.25/0.24 1.0 (0.7–1.3) 0.2 ns 1.4 ns
rs160948 CNTNAP4 T 0.25 3.0 0.003 A 2.0 0.04 0.25/0.24 0.9 (0.7–1.3) 0.4 ns 1.1 ns
rs6564312 CNTNAP4 C 0.63 2.5 0.01 D 2.0 0.04 0.65/0.65 0.7 (0.4–1.1) 1.5 ns 2.5 0.01
rs7196352 CNTNAP4 A 0.39 1.9 0.05 D 1.5 ns 0.43/0.39 0.9 (0.6–1.4) 0.3 ns 1.3 ns
rs768503 ADAMTS18 A 0.14 2.5 0.01 A 1.2 ns 0.10/0.12 1.2 (0.8–1.7) 0.8 ns 0.3 ns
rs8059387 ADAMTS18 T 0.85 2.5 0.01 D 1.5 ns 0.86/0.88 0.9 (0.1–6.6) 0.1 ns 1.0 ns
rs7198627 ADAMTS18 C 0.46 2.3 0.02 D 1.2 ns 0.45/0.46 1.0 (0.7–1.5) 0.1 ns 0.9 ns
rs2943768 WWOX G 0.16 2.4 0.02 A 2.0 0.05 0.19/0.21 1.2 (0.9–1.6) 1.0 ns 2.1 0.04
rs2287951 WWOX C 0.15 2.7 0.007 D 2.2 0.03 0.21/0.22 1.2 (0.8–1.7) 0.9 ns 2.2 0.03
rs2548861 WWOX T 0.38 2.6 0.01 D 3.2 0.001 0.39/0.45 2.0 (1.4–3.0) 3.6 0.0004 4.8 1.4 3 106
rs2656612 WWOX C 0.14 2.3 0.02 D 1.8 0.08 0.14/0.16 1.2 (0.8–1.8) 0.9 ns 1.8 0.06
rs1111230 WWOX C 0.52 2.4 0.01 D 1.6 ns 0.52/0.47 0.9 (0.6–1.4) 0.3 ns 1.0 ns
rs4517809 MAF A 0.38 2.3 0.02 D 1.8 0.07 0.43/0.35 0.6 (0.4–0.9) 2.4 0.02 3.0 0.003
rs1110789 MAF T 0.48 2.7 0.006 D 2.0 0.04 0.48/0.49 1.2 (0.8–1.9) 0.9 ns 0.8 ns
rs1126264 MAF T 0.15 2.4 0.02 A 1.7 0.08 0.14/0.16 1.1 (0.8–1.6) 0.6 ns 1.6 ns
rs1433157 CDH13 G 0.52 2.3 0.02 D 2.1 0.04 0.52/0.52 1.0 (0.6–1.5) 0.1 ns 1.5 ns
rs8046812 CDH13 G 0.22 2.3 0.02 D 1.8 0.08 0.22/0.23 1.0 (0.7–1.4) 0.2 ns 1.4 ns
rs4598906 CDH13 T 0.40 3.2 0.001 D 1.3 ns 0.30/0.34 1.2 (0.8–1.7) 0.9 ns 1.6 ns
rs7498488 CDH13 G 0.29 3.3 0.0008 A 1.6 ns 0.32/0.33 1.0 (0.8–1.3) 0.2 ns 1.0 ns
rs2228685 CDH13 A 0.56 2.8 0.005 D 1.8 0.07 0.54/0.54 1.0 (0.6–1.6) 0.04 ns 1.3 ns
rs4366698 CDH13 C 0.69 2.9 0.004 D 0.9 ns 0.69/0.68 0.7 (0.4–1.2) 1.3 ns 1.5 ns
rs4238692 CDH13 T 0.28 2.2 0.03 D 2.6 0.009 0.28/0.28 1.1 (0.8–1.6) 0.4 ns 2.1 0.03
a Allele frequency in the stage 1 and 2 families combined.
b Model indicates the genetic model that provided the most significant result in the joint analysis of the family-based samples. A indicates the additive
model and D indicates the dominant model.
c The 50 Finnish dyslipidemic stage 1 families and 52 European-descended dyslipidemic stage 2 families were included in this analysis.
d Allele frequency in the European-descended dyslipidemic controls and cases.
e OR (95% CI) indicates the odds ratio and 95% confidence interval. The SNP that was significant after Bonferroni correction for multiple testing is
indicated in bold. ns indicates pR 0.1.All statistical analyses of the population-based cohorts were per-
formed with the SPSS 15.0 software. Because the METSIM and
Young Finns studies represent unascertained population-based
samples, we assessed the effect of rs2548861 on continuous
HDL-C measurements. We used independent t tests with a domi-
nant model of inheritance coded as G/G ¼ 0 and both T/T and
G/T¼ 1 as an independent variable, consistent with the dominant
mode of inheritance observed in the stage 1 and 2 analysis. We
used standardized HDL-C residuals (Z scores, mean ¼ 0 and stan-
dard deviation [SD] ¼ 1) prepared separately by sex when applica-
ble and adjusted for the ln(BMI) and age. In the Young Finns
cohort we analyzed the average of the 4 HDL-C measurements
taken in 1980, 1983, 1986, and 2001, as well as each year individ-
ually. In the METSIM cohort, we also performed the association
analysis by excluding subjects reimbursed for medication for the
treatment of T2DM or coronary heart disease (i.e., a lipid-lowering
drug) as well as subjects with BMI greater than the Finnish age-
and sex-speciﬁc 90th percentile35 because these factors are known
to alter serumHDL-C levels. Marginal effect sizes (ES) were directly
calculated on the basis of the t-statistics (ES ¼ t 3 sqrt[[n0 þ n1]/
[n0 3 n1]], ni ¼ number of subjects coded as i). The effect size rep-
resents the proportion of one-standard-deviation change in stan-
dardized HDL residual (adjusted for covariates) for a carrier of
the T risk allele. In the Young Finns cohort, the longitudinalThe Amedata were analyzed by repeated-measures analysis of variance
(RANOVA), for which we assumed a dominant model of inheri-
tance as a categorical factor and used HDL-C measurements taken
in 1980, 1983, 1986, and 2001 as dependent repeated variables.
Consistent with the independent t test, we used age and ln(BMI)
adjusted Z scores prepared separately by sex as the dependent vari-
able in the model for the RANOVA analysis. In the METSIM
cohort, HDL-C values greater than 4 standard deviations from
the mean were excluded as outliers (ten subjects), and in the
Young Finns cohort, only participants with complete data for
the four different time points of the follow-up study were included
(n ¼ 1,561). We also performed a combined analysis of the
METSIM and Young Finns cohorts by using a combined statistic.
We calculated an overall statistic weighted by the square root of
the proportion of individuals examined in each cohort to calculate
the corresponding p value.12,31
Luciferase Reporter Assay
A 691 bp region of high conservation surrounding the associated
rs2548861 and including the predicted cis-regulatory element
was cloned into the TOPO-TA vector (Invitrogen, Carlsbad, CA)
with the following primers: 50-TCATGTTCCCTTCGGAAAAC-30
and 50-TTTGTGTGTACAGACTCCAGGTG-30. The DNA fragmentsrican Journal of Human Genetics 83, 180–192, August 8, 2008 183
were subcloned into pGL3-promoter vector (Promega, Madison,
WI) by use of the SalI- and BamHI-cloning sites downstream of
the luciferase reporter transcript. The rs2738572-rs2548861 haplo-
types C-G and A-Twere produced from the haplotype C-Twith the
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer’s protocol. HepG2 cells were
cultured in MEM supplemented with 10% fetal bovine serum,
100 I.U./ml penicillin, and 100 mg/ml streptomycin (Cellgro,
Mediatech Inc., Manassas, VA) and transiently transfected by Lip-
ofectamine 2000 reagent (Invitrogen) according to the manufac-
turer’s protocol on 48-well plates. At approximately 80% conﬂu-
ence, each well was transfected with 400 ng of the experimental
reporter gene (pGL3-promoter vector constructs) and 27 ng of
the transfection control plasmid pRL-TK (Promega) encoding the
renilla luciferase gene. Growthmedium (200 ml) without penicillin
and streptomycin was added 24 hr after transfection. The lucifer-
ase activity of each construct was measured six times, and the dif-
ferent constructs were compared with a two-tailed t test under an
assumption of equal variance. Error bars represent the SD. The
luciferase activity was measured with the dual-luciferase reporter
assay system (Promega), which uses the renilla luciferase signal
to normalize the luciferase intensity. Cells in each well were lysed
with 100 ml lysis buffer, and luciferase activity was measured from
30 ml of cell lysate with a luminometer (GloMax 96 Microplate
Luminometer, Promega).
EMSA
The nuclear proteins were extracted from the HepG2 cell line by
NE-PER nuclear-extraction reagents (Pierce, Rockford, IL), and pro-
tein concentrations were quantiﬁed by the Bradford assay.
Complementary 50 biotinylated and unlabeled oligonucleotide
probes 50-ACCATTCAAATCTT(T/G)CCCTCACAGGACAAT-30 and
50-ATTGTCCTGTGAGGG(A/C)AAGATTTGAATGGT-30, represent-
ing both alleles of rs2548861, were commercially obtained
(Operon Biotechnologies). For the EMSA, nuclear proteins (5 mg)
were preincubated in binding buffer (10 mM Tris-HCl [pH 7.5];
50 mM NaCl; 1 mM dithiothreitol; 1 mM EDTA; and 5% glycerol)
for 10 min with or without the unlabeled double-stranded speciﬁc
competitor probe in 200-foldmolar excess (4 pmol). Subsequently,
the biotin-labeled double-stranded oligonucleotide probe (~20
fmol) was added to 20 ml of total reaction volume, and the mixture
was kept at room temperature for 30 min, followed by 15 min on
ice. For the competition EMSA experiment, nuclear proteins were
preincubated in binding buffer with unlabeled double-stranded
allele-speciﬁc competitor probes in 25-, 50-, and 100-fold molar
excess for 10 min. As a nonspeciﬁc competitor, an unlabeled
scrambled oligonuceotide with the same base composition as
that of the probes was used at 200-fold molar excess. Reactions
were analyzed on a 6% Novex DNA retardation gel (Invitrogen)
that was electroblotted onto a positively charged nylon mem-
brane. The biotin-labeled probe (~20 fmol) in binding buffer with-
out the addition of nuclear protein extract and competitor probe
was used as the negative control. Detection of a shift in the mobil-
ity of the biotin-labeled probe was achieved after incubation of the
membrane with streptavidin-horseradish peroxidase and develop-
ment with luminol substrate (Pierce; Lightshift Chemilumines-
cent EMSA kit). Light emission was captured on X-ray ﬁlm.
Expression Analysis ofWWOX
The expression of the full-length isoform1ofWWOXwas analyzed
by RT-PCRwith theHumanMultiple Tissue cDNApanel 1 (MTC-1)184 The American Journal of Human Genetics 83, 180–192, August 8(Clontech, Mountain View, CA) and cDNA obtained from adipose
tissue (Invitrogen, Carlsbad, CA). A 106 bp fragment was ampliﬁed
with primer pairs 50-ATGGTGCACATGTGATCTTGGCCT-30 and
50-AGGGTCATTGCTTCTACCTTGGCT-30, under the following
conditions: 94C for 10 min, 35 cycles of 94C for 30 s, 61C for
30 s, 72C for 30 s, and then by 72C for 8 min. A 983 bp fragment
of the housekeeping gene glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH [MIM 138400]) was also ampliﬁed from the same
cDNAs under the same PCR conditions with primers provided by
the manufacturer (Clontech, Mountain View, CA). The PCR prod-
ucts were then electrophoresed on a 1.5% agarose/EtBr gel.
Results
Stage 1 Association Analysis
We utilized a two-stage design to investigate a 12.4 Mb
region on chromosome 16q23-q24 with LOD scores within
1.0 of the highest LOD score in the combined Dutch/Finn-
ish linkage analysis4 and including the Mexican American
linkage peak.6 In this design, we genotyped all 1,318 re-
gional tag SNPs in Finnish dyslipidemic families to screen
for association signals in stage 1.We genotyped potentially
positive signals in the stage 2 dyslipidemic families and case
and control study samples, and we performed a combined
analysis of the two stages to identify the variants that
were of region-wide signiﬁcance. Skol et al.31 originally
introduced this design to reduce the cost of genotyping in
stage 1 while maintaining the overall power of the study.
In stage 1, a total of 1,318 SNPs were tested for associa-
tion via the additive model in 50 Finnish dyslipidemic
families with positive evidence of linkage to the region
for the low HDL-C trait; option e of the FBAT software,
which tests for association in the presence of linkage,
was used. We also included tagSNPs for the LCAT and
CETP genes, even though they are located outside of the
LOD 1 region, because they are highly relevant func-
tional candidates that were also implicated for HDL-C in
the recent GWAS ascertained for T2DM.11,12 The clinical
characteristics of all study samples are presented in Table
S1. The most signiﬁcant association was observed for
rs7498488, within the CDH13 gene (p ¼ 0.0008) (Figure 1,
Table 1). In addition, 14 SNPs located within or near
ATBF1, CNTNAP4, ADAMTS18, WWOX, and CDH13 and
in the intergenic region between the MAF and DYNLRB2
genes were associated at a signiﬁcance level of p % 0.01
(Figure 1, Table 1). We selected 15 SNPs that provided
p % 0.01, as well as ten SNPs within these genes or inter-
genic regions with p values less than 0.05, resulting in a to-
tal of 25 SNPs that were studied again in stage 2. The SNPs
within the CETP and LCAT genes did not result in p values
< 0.05 in stage 1 for the qualitative low HDL-C trait in the
Finnish families.
Stage 1 and 2 Association Analysis
The 25 SNPs selected from the stage 1 analysis were tested
in a joint analysis of the stage 1 and 2 families by the same
method as in stage 1, with FBAT option e, and both the, 2008
Figure 1. Association Results of Stage
1 and Combined Analyses of Stages 1
and 2
The log10 of the p values obtained from
the stage 1 FBAT e analysis and the com-
bined analysis of stage 1 and 2 study
samples are shown. Black circles represent
the 25 stage 1 SNPs that were re-examined
in the stage 2 study samples. Results of the
combined analysis of stage 1 and 2 family-
based and case-control samples are shown
in larger open circles (for details of analy-
sis model, see Table 1). The open triangle
indicates the result of the overall com-
bined analysis of all dyslipidemic samples
(n ¼ 3,070). Small gray circles are the
1293 stage 1 SNPs that were not re-exam-
ined in the stage 2 samples. p ¼ 3.7 3
105 indicates the Bonferroni corrected
significance threshold.additive and dominant models were tested (Table 1). This
analysis included a total of 102 dyslipidemic families (50
Finnish and 52 European-descended families; n ¼ 933).
The SNP rs2548861 within WWOX was the most signiﬁ-
cantly associated SNP, with p ¼ 0.001 for the dominant
model and the same T risk allele as in stage 1 (Table 1).
We also analyzed the 25 SNPs in 475 European-descended
low-HDL-C cases and controls for the additive and domi-
nant models by using the logistic regression test. Consis-
tent with the family-based results, the rs2548861 SNP in
WWOX was also associated with the dominant model
and the same T risk allele in the cases and controls (p ¼
0.0004, OR ¼ 2.0, 95% CI ¼ 1.4–3.0) (Table 1). Thus, one
copy of the T allele of rs2548861 increases the probability
for low HDL-C by approximately 17% in this case-control
study sample. Two SNPs within ATBF1, rs2157786 and
rs8056528, were also signiﬁcant in the family-based analy-
sis (p ¼ 0.003 for both SNPs), but not in the case-control
samples (p> 0.4) (Table 1). Next, we performed a combined
analysis of the stage 1 and 2 family and case-control study
samples for the 25 SNPs by combining the Z statistics, as
described in the Material and Methods. We observed a sig-
niﬁcant association between rs2548861 and low HDL-C
(p ¼ 1.4 3 106) for the dominant model and the same T
risk allele (Figure 1). This result is region-wide signiﬁcant:
It surpasses the Bonferroni correction for the 1318 SNPs
tested in stage 1, as well as the two models tested for 25
SNPs in the combined analysis of stage 1 and 2 (Bonferroni
adjusted p ¼ 0.002) (Figure 1).
For the rs2548861 SNP that was identiﬁed to be region-
wide signiﬁcant by our two-stage study design, we
included all available subjects of the stage 1 and 2 families,The Amthe case-control subjects, and 55Mexican FCHL families in
an overall combined analysis of family-based and case-con-
trol samples (n ¼ 3,070) and observed a p value of 6.9 3
107 (Bonferroni adjusted p ¼ 0.0009) (Figure 1). We also
estimated the empirical signiﬁcance of this overall com-
bined statistic for rs2548861 in all of the dyslipidemic
study samples (n ¼ 3,070) by combining the statistics
obtained from 50,000 random permutations of the case-
control status and 50,000 random gene-dropping proce-
dures in the families to estimate the p value. All 50,000
permuted statistics were less signiﬁcant than Z ¼ 4.96
obtained for rs2548861. Because the gene-dropping proce-
dure is computationally intensive, we limited the number
of permutations to 50,000, which is the number necessary
for exceeding the Bonferroni correction of p ¼ 3.7 3 105.
To summarize, we observed an association of region-wide
signiﬁcance between rs2548861 and low HDL-C for the
dominant model and the same risk allele consistently
throughout our family-based and case-control study sam-
ples (n ¼ 3,070).
We performed subset linkage analyses as previously de-
scribed33 to examine whether the SNP rs2548861 explains
the linkage at 16q23-q24 for low HDL-C.4 We used the
viewstat -e option of FBAT to divide the 62 FCHL and
low-HDL-C families of the original linkage study4 into as-
sociated and unassociated families based on whether the
family contributed positively to the Z-score statistic of
FBAT. For rs2548861, the 20 associated, the 42 unassoci-
ated, and all 62 families produced LOD scores of 2.6, 0.7,
and 3.9, respectively, at the peak location (D16S518–
D16S3096) (Figure S1), suggesting that rs2548861 explains
much of the linkage. The WWOX gene is located directlyerican Journal of Human Genetics 83, 180–192, August 8, 2008 185
Table 2. Association of rs2548861 in the METSIM and Young Finns Population-Based Cohorts
Study Sample N Allele Frequency
HDL-C (mg/dl)c
Pd Effect size (SEM)eGG GT TT
METSIM Cross-Sectional Cohort of Finnish Males
ALL 4,447 57.35 0.43 56.3 5 0.30 56.2 5 0.42 0.03 0.08 (0.03)
DM and CAD exclusiona 3,727 0.49 58.55 0.47 57.0 5 0.33 57.2 5 0.46 0.009 0.10 (0.04)
DM, CAD and BMI exclusiona,b 3,403 59.45 0.49 57.6 5 0.35 57.9 5 0.48 0.003 0.12 (0.04)
Young Finns Study: Prospective Cohort of Young Finnish Subjects
1980–2001 mean 59.55 0.48 58.2 5 0.34 57.9 5 0.48 0.004 0.14 (0.05)
1980 62.05 0.59 60.0 5 0.42 60.0 5 0.60 0.002 0.18 (0.06)
1983 1,561 0.50 65.85 0.65 64.9 5 0.46 64.3 5 0.65 0.08 0.10 (0.06)
1986 59.85 0.55 58.6 5 0.39 57.7 5 0.55 0.01 0.15 (0.06)
2001 50.65 0.54 49.2 5 0.38 49.5 5 0.55 0.04 0.12 (0.06)
a Exclusion of subjects receiving government-subsidized medication for the treatment of diabetes and CAD from the analysis.
b Exclusion of subjects with BMI greater than the age- and sex-specific Finnish 90th percentiles.
c Values shown are the estimated marginal mean5 SEM of HDL-C after adjustment for age, BMI, and sex, when applicable.
d p values were obtained by independent t tests between the GG genotype and TX genotype carriers (i.e., TT and TG genotypes) by the use of standardized
HDL-C residuals (mean ¼ 0 and SD ¼ 1) that were corrected for age, BMI, and sex, when applicable (see Material and Methods).
e The effect size represents the proportion of 1 SD change in standardized HDL-C residual values for the presence of the T risk allele.under the linkage peak (Figure S1). However, a shoulder of
the linkage signal (105–110 cM) remains unexplained by
rs2548861 (Figure S1), suggesting that additional variants
in the 16q23–q24 region might confer susceptibility for
low-HDL-C levels.
Investigation of a Population Effect of rs2548861
in the METSIM and Young Finns Cohorts
To extend our investigation to nondyslipidemic and unas-
certained population study samples, we examined the
rs2548861 SNP in two independent population-based
cohorts for association with HDL-C levels. The dominant
genetic model resulted in the most signiﬁcant association
in the stage 1 and 2 dyslipidemic study samples. In both
the METSIM and Young Finns cohorts, the carriers of the
T allele also had lower HDL-C levels than the GG genotype
carriers (Table 2), further supporting the dominant model.
Therefore, we compared the mean of the standardized
HDL-C levels adjusted for BMI between the nonrisk GG
carriers against the T risk allele carriers (TX, i.e., genotypes
TT and TG) by an independent t test.
The METSIM cohort consists of Finnish males between
50 and 70 years of age. We observed a signiﬁcant associa-
tion between the rs2548861 genotype and HDL-C levels
in the total study sample; lower HDL-C levels were
observed in the TX genotype carriers (p ¼ 0.03, n ¼
4,447) (Table 2). The effect size as calculated directly based
on the t statistic was 0.08 (SEM ¼ 0.03) which corre-
sponds to 0.08 of the standard deviation in standardized
HDL-C residual for a carrier of the T risk allele. Exclusion of
subjects receiving government-subsidized medication for
the treatment of diabetes or coronary heart disease (i.e.,
lipid-lowering drugs), which are known to alter serum
HDL-C levels, improved the association (p ¼ 0.009, n ¼
3,727) and increased the effect size (0.10, SEM ¼ 0.04)
(Table 2). Furthermore, exclusion of obese subjects with186 The American Journal of Human Genetics 83, 180–192, Augustage- and sex-speciﬁc BMI greater than the Finnish popula-
tion 90th percentile provided additional signiﬁcance to the
association (p ¼ 0.003, n ¼ 3,403) and further increased
the effect size (0.12, SEM ¼ 0.04) (Table 2).
The Young Finns study sample is a population-based pro-
spective cohort of young Finnswhowere aged 3–18 years at
the time of enrollment in the study in 1980 and were fol-
lowed for 21 years. Adjusting for sex andmeasurement-spe-
ciﬁc age and BMI , we analyzed themean of the four HDL-C
measurements obtained between 1980 and 2001 for the
dominant model of inheritance. We excluded from the
analysis subjects receiving treatment for diabetes (n ¼ 8)
and lipid-lowering drugs (n ¼ 3). We observed a signiﬁcant
association between rs2548861 and the mean of the four
HDL-C measurements; lower HDL-C levels were observed
in theTXgenotype carriers (p¼0.004, n¼1,561), and there
was an effect size of 0.14 (SEM ¼ 0.05). The TX genotype
explains 1.5% of the variance in HDL-C levels in these sub-
jects, representative of the unascertained population of
both sexes and a broad age range. To fully utilize the pro-
spective feature of the phenotypic data, we examined the
longitudinal effect of rs2548861 on HDL-C levels by
RANOVA and found a signiﬁcant association between the
dominant model of rs2548861 and the variance of HDL-C
levels observed in four repeated measurements obtained
over a span of 21 years (p ¼ 0.003) (Figure 2).
We performed a combined analysis of the METSIM and
Young Finns cohorts by using a combined statistic
weighted by the proportion of the cohorts and using sim-
ilar exclusion criteria aimed at eliminating users of diabetes
and lipid-lowering drugs. In the combined statistic of
5,288 subjects, we obtained a p value of 0.0004 for the as-
sociation between rs2548861 and HDL-C. Exclusion of
obese subjects with age- and sex-speciﬁc BMI greater
than the population 90th percentile from both cohorts in-
creased the signiﬁcance to p ¼ 1.95 3 105 (n ¼ 4,828).8, 2008
Resequencing of theWWOX Gene
We resequenced the exons and exon-intron boundaries of
WWOX in 16probandsof the Finnishdyslipidemic families
that provided evidence of microsatellite linkage to 16q23-
q24 and evidence of association with the rs2548861 SNP.
We identiﬁed one nonsynonymous SNP, rs12918952 in
exon 6 of isoform 1; this SNP has a minor allele frequency
(MAF) of 0.44 and results in Ala179Val substitution (Table
S2). This SNP was tagged by rs4888786 (r2 ¼ 0.88, D0 ¼
0.96), which was analyzed in our stage 1 Finnish dyslipi-
demic families and was not signiﬁcantly associated with
the low-HDL-C trait (p ¼ 0.63). In addition, we identiﬁed
one rare synonymous variant, ss104806834 in exon 7
(MAF ¼ 0.03), as well as twelve intronic SNPs and seven
SNPs in the 30 UTR (Table S2). None of the variants identi-
ﬁed by sequencing are in LD with the associated
rs2548861 (r2% 0.1, D0 % 0.26) and, therefore, cannot ac-
count for the association observed in our genetic analysis.
Functional Analysis of rs2548861
The extent of LD across the WWOX gene in the 50 pro-
bands of the stage 1 Finnish dyslipidemic families and as-
sociation results for the WWOX SNPs in the two stages
are shown in Figure S2A. The LD (r2 > 0.5, D0 > 0.7)
extends to tag SNPs immediately surrounding the
rs2548861 SNP (Figure S2A). However, because the associ-
ation evidence obtained with our two-stage design was
Figure 2. A Profile Plot of the General Linear Model Showing
the Longitudinal Effect of rs2548861 on HDL-C Levels in the
Young Finns Cohort
The circles represent the estimated marginal means of the stan-
dardized HDL-C residual values of measurements obtained in the
corresponding year for the GG genotype carriers and the squares
represent the TX carriers. TX indicates carriers of the T risk allele,
i.e., genotypes TT and TG. The p value was obtained by RANOVA
analysis for the standardized HDL-C residuals corrected for age,
sex, and BMI.The Amemost signiﬁcant for rs2548861, we prioritized this particu-
lar HDL-C-associated variant for our functional inves-
tigation. The rs2548861 is a tag SNP that captures two
additional SNPs, rs2738577 and rs2550606, with r2 of
0.93 (D0 ¼ 1.0) and 0.96 (D0 ¼ 1.0), respectively, in the Eu-
ropean-descended CEU subjects of the HapMap project. All
three SNPs are located in the large intron 8 ofWWOX. We
focused our functional analysis on rs2548861 because it is
located within a 235 bp predicted conserved element by
the phastCons program36 on the basis of whole-genome
alignments of vertebrates (LOD ¼ 734 out of a possible
1,000), as well as the placental-mammal subset of species
(LOD ¼ 431) (UCSC Genome Browser). Additionally,
211 bp of the same region was computationally predicted
to function as a cis-regulatory element because of the sig-
niﬁcant conservation observed for the human-mouse-
chicken and human-mouse-frog alignments (p < 0.001),
as well as the absence of overlap with exons of any known
genes, mRNA, or spliced expressed sequence tags (VISTA
Enhancer Browser)37 (Figure S2B).
We resequenced a 525 bp region surrounding the pre-
dicted regulatory element in 48 Finnish dyslipidemic and
24 Dutch FCHL probands. We identiﬁed an additional
common variant, rs2738572 (MAF ¼ 0.35 and r2 ¼ 0.49
[D0 ¼ 0.86] with rs2548861). The variant rs2738572 is lo-
cated 162 bp centromeric to rs2548861 and 70 bp outside
of the predicted regulatory element, but still within a re-
gion of high conservation. We followed up on this SNP in
the stage 1 Finnish dyslipidemic families and observed no
evidence of single-SNP- or haplotype-based association
with rs2548861 for the HDL-C trait (p > 0.1). In summary,
rs2548861 is the only common variant within the 211 bp
predicted cis-regulatory element and within the larger 526
bp conserved region to be associated with the low-HDL-C
trait.
We performed a luciferase reporter assay to test the func-
tion of this conserved, predicted regulatory element. We
cloned a 691 bp region that includes the rs2548861 SNP
and the predicted cis-regulatory region into the pGL-3 pro-
moter vector downstream of the luciferase reporter gene.
We tested the three common regional haplotypes of
rs2738572–rs2548861 (H1–H3) with frequency > 0.05 in
the forward and reverse orientation in the HepG2 cell
line. H1 represents a haplotype of C-G alleles, H2 of A-T,
and H3 of C-T for the SNPs rs2738572–rs2548861, respec-
tively. The haplotypes H2 and H3 contain the T risk allele
of rs2548861, and the haplotype H1 has the non-risk G
allele. We used HepG2 cells for these experiments, because
the liver is a highly relevant tissue involved in HDLmetab-
olism. We used RT-PCR to verify the expression ofWWOX
in HepG2 cells (data not shown), as well as in normal liver
cells (Figure S3). We assayed for luciferase activity 48 hr
after transfection and observed a signiﬁcant reduction in
the reporter activity for the H1, H2, and H3 haplotype
constructs in the reverse orientation when these were com-
pared to the empty vector, suggesting that this region func-
tions as a cis-regulatory element (p ¼ 0.008, 0.003, 0.002,rican Journal of Human Genetics 83, 180–192, August 8, 2008 187
Figure 3. Evidence of rs2548861 Allele-Specific Cis-Regulatory Function
(A) A luciferase reporter assay demonstrates a cis-regulatory function for the 691 bp region surrounding rs2548861, and a significant
allelic effect is observed. H1–H3 represent the common haplotypes of the SNPs rs2738572 and rs2548861 with frequency greater than
0.05 that were identified in the region by resequencing. The H1 haplotype is composed of the C-G alleles, H2 of A-T, and H3 of C-T
for the rs2738572–rs2548861 haplotypes, respectively. The haplotypes H2 and H3 contain the T risk allele of rs2548861, and the hap-
lotype H1 has the nonrisk G allele. Error bars represent the SD.
(B) A comparative EMSA demonstrates the formation of a DNA-nuclear-factor complex in the 25 bp sequence surrounding the rs2548861
SNP with preferential nuclear-factor binding for the G allele. The lanes T and G indicate the allele of rs2548861 contained in the 25 bp
biotin-labeled probe. The position of the unbound probe is indicated. An arrowhead indicates the position of the DNA-nuclear factor
complex; /, the negative control; þ/, the addition of nuclear extract; and þ/þ, the addition of nuclear extract and a 200-fold
excess of unlabeled competitor probe in the binding reactions, respectively.respectively) (Figure 3A). We also observed a highly signif-
icant allelic effect of rs2548861 on the reporter activity:
Haplotypes H2 and H3 carrying the T risk allele of
rs2548861 had signiﬁcantly lower luciferase activity than
the H1 haplotype with the nonrisk G allele (p ¼ 0.0004,
5.33 106, respectively) (Figure 3A). This signiﬁcant effect
was observed in three independent experiments. Consis-
tent with our association results for the rs2738572–
rs2548861 haplotype, we did not observe any differences
in the reporter activity between the H2 and H3 haplotypes
that have the T risk allele of rs2548861 versus either the A
or C allele of rs2738572 (p ¼ 0.3) (Figure 3A). Therefore,
the 691 bp region surrounding the rs2548861 SNP func-
tions as a cis-regulatory element in vitro, and rs2548861
has a signiﬁcant allelic effect on this regulatory function.
We also examined the 25 bp region surrounding the SNP
rs2548861 by comparative EMSA by using HepG2 cell nu-
clear extract that had been used in the reporter assay. We
observed the presence of a DNA-nuclear-factor complex
with both the G and Talleles (Figure 3B). However, binding
of the nuclear factor appeared to be preferential for the
nonrisk G allele in three independent experiments
(Figure 3B). To further assess the difference in binding
afﬁnity between the G and T alleles in a more quantitative
manner, we performed a competition EMSA experiment by
using unlabeled allele-speciﬁc competitor that was titrated
in 25-, 50-, and 100-fold molar excess of the biotin-labeled
probe. These data show that the unlabeled allele-speciﬁc
competitor disrupts the shift of the T-allele probe at a lower
molar excess than the G-allele probe (Figure S4A). The
DNA-nuclear-factor complex also appears to be speciﬁc188 The American Journal of Human Genetics 83, 180–192, Augustgiven that a 200-fold molar excess of the nonspeciﬁc com-
petitor did not compete for binding as effectively as the
speciﬁc competitor (Figure S4B). The EMSA data are repre-
sentative of at least three independent experiments. Thus,
the sequence immediately surrounding rs2548861 binds
nuclear factors in an allele-speciﬁc manner, providing
additional evidence that the rs2548861 SNP might inﬂu-
ence the putative cis-regulatory function of the surround-
ing region.
Lastly, we performed expression analysis of the WWOX
transcript by using cDNA obtained from a panel of human
tissues by RT-PCR. These data show normal expression of
WWOX in the liver and other tissues relevant for HDL
metabolism, including the adipose, pancreas, and skeletal
muscle (Figure S3).
Comparison with the GWAS Results for HDL-C Levels
Recently, the GWAS data of the Diabetes Genetics Initiative
(DGI), the FUSION study of type 2 diabetes, and the Sardi-
NIA study of aging-associated variables cohorts were ana-
lyzed for lipid traits, including HDL-C.11,12 We examined
these publicly available GWAS results for association
evidence for HDL-C in the 12.4 Mb linked region on
16q23–q24. We observed that rs2548861 SNP or SNPs in
LD were not signiﬁcant in these GWAS studies predomi-
nantly ascertained for T2DM.12 However, a WWOX SNP,
rs2667590, located in the same intron as our associated
SNP rs2548861, was the most signiﬁcantly associated
SNP in the 12.4 Mb region (p ¼ 2.3 3 105), and it ranked
344th among 2,559,602 SNPs tested for HDL-C in the en-
tire GWAS study, which was mostly based on T2DM cases8, 2008
and controls.12 There is no LD between rs2667590 and
rs2548861 in the CEU subjects of the HapMap Project
(r2 < 0.02). This SNP rs2667590 (MAF ¼ 0.03) represents
a cluster of SNPs in tight LD, and none of these SNPs
were included in our study because our tagging strategy
focused on SNPs with a MAF > 0.10.
Discussion
In the current study, we observed a region-wide signiﬁcant
association between HDL-C and aWWOX variant that has
an allele-speciﬁc cis-regulatory function. We performed
targeted genotyping of a region of linkage on chromosome
16q23–q24 by utilizing a two-stage association analysis of
regional tag SNPs. We identiﬁed an association of region-
wide signiﬁcance between rs2548861 within WWOX and
low HDL-C in dyslipidemic families and case-control sub-
jects. Furthermore, we observed a signiﬁcant population
effect of this SNP rs2548861 on the HDL-C levels in
a cross-sectional cohort of Finnishmales of age 50–70 years
(METSIM cohort), as well as a longitudinal effect on the
HDL-C levels in the prospective Young Finns cohort,
whose subjects were followed for 21 years. Overall, our
genetic analysis showed signiﬁcant associations between
HDL-C levels and rs2548861 for the same risk allele and
dominant model in a total of 9,798 subjects analyzed for
this variant. The multiple lines of evidence obtained
from a diverse array of study samples, ranging from ascer-
tained dyslipidemic families and case-control subjects to
population-based cross-sectional and prospective cohorts,
further substantiates a role of rs2548861 in determining
serum HDL-C levels.
We observed that a copy of the T allele of rs2548861 in-
creased the probability of having low HDL-C by 17% in
the low-HDL-C case-control study sample. In the unascer-
tained Young Finns population cohort, one copy of the
T allele explains 1.5% of the variance in HDL-C levels.
Because numerous genetic and environmental factors con-
tribute to the expression of serum HDL-C levels, the effect
of the rs2548861 susceptibility allele is likely to be more
pronounced in comparisons of low-HDL-C individuals car-
rying additional risk factorswith healthy controls. Our data
suggest that this SNP rs2548861 alone is not amajorHDL-C
determinant but rather that it is a modiﬁer variant that
inﬂuences serum HDL-C levels, in line with rapidly accu-
mulating evidence that numerous common variants each
with a minor to modest effect size contribute to the expres-
sion of a complex trait.11,12,38–41 Although the association
with rs2548861 explains much of the original linkage evi-
dence, a shoulder of linkage signal remains unexplained
by rs2548861. Therefore, it is possible that other genes
residing in the 16q23–q24 region also contribute to the
linkage results observed for HDL-C in different study sam-
ples. Clarifying the overall role of WWOX on HDL-C levels
warrants extensive resequencing in larger study samples of
low-HDL-C cases and controls so that rare variants of largeThe Ameffect onHDL-C levels can be identiﬁed. The effect sizes ob-
served in our population-based study samples (0.08 to
0.18) are in the same range as the effect sizes (0.07 to
0.18) observed for HDL-C-associated variants in the re-
cent GWASs predominantly ascertained for T2DM.11,12 It
is worth noting that our study estimated the effect at the
population level, whereas the estimated effects of the
GWASs11,12 do not reﬂect the general population and
cannot be directly extended to unascertained populations.
The SNP rs2667590 resulted in a p value of 2.33 105 for
HDL-C in the meta-analysis of the GWAS on the basis of
T2DM cases and controls.12 Importantly, this SNP was
the most signiﬁcantly associated SNP in the GWAS12 for
the 12.4 Mb region that we analyzed in the present study.
However, rs2548861 was not signiﬁcantly associated with
HDL-C levels in this GWAS for lipid traits when an additive
model was used.11,12 It is possible that different variants of
the same gene inﬂuence HDL-C levels in subjects with
T2DM and dyslipidemia. We observed that 49% of the
DGI and 40% of the FUSION subjects of the GWAS stage
1 had T2DM12 but that 7% of subjects had T2DM in our
stage 1 dyslipidemic families. Furthermore, our association
with rs2548861 was consistently observed with the domi-
nant model throughout the 9,798 study samples, whereas
the additive model was used for analyzing this SNP in the
GWASs.12 Moreover, in our analysis of the two population-
based METSIM and Young Finns cohorts, exclusion of in-
dividuals with diabetes and/or high BMI improved our
association signal, suggesting that the presence of diabetes
or the highly related obesity trait might confound the as-
sociation with rs2548861. However, the presence of two
independently associated variants located in the same in-
tron 8 of the WWOX gene for HDL-C levels in our study
and the GWAS of the predominantly T2DM-based study
sample analyzed for lipids12 is particularly noteworthy be-
cause it provides independent, yet complementary, sup-
port of a role of the WWOX gene in HDL-C metabolism.
Previously, in vivo enhancer analysis of human con-
served noncoding sequences in transgenic mice identiﬁed
a functional enhancer element also located in intron 8 of
WWOX.42 Moreover, cell lines derived from the gastric ad-
enocarcinoma AGS exhibit three distinct regions of homo-
zygous deletions in intron 8 of WWOX.43 Our functional
data obtained from the reporter assay and EMSA implicate
a cis-regulatory function of the intron 8 conserved region
where rs2548861 resides. The cis-regulatory function and
the allelic effects warrant further investigation because
these artiﬁcial in vitro systems do not necessarily reﬂect
the normal physiological state. However, the statistically
signiﬁcant reporter assay results and the EMSA experi-
ments are intriguing ﬁrst lines of evidence that implicate
a functional variant within a functional cis-regulatory
element that inﬂuences serum HDL-C levels.
The WWOX gene encodes a 46 kDa protein that con-
tains two WW domains and a short-chain oxidoreductase
(SDR) domain.44 WWOX regulates transcription by bind-
ing to the proline-rich ligand of its targeted transcriptionerican Journal of Human Genetics 83, 180–192, August 8, 2008 189
factors via the WW domain in the cytoplasm and prevent-
ing translocation into the nucleus. The SDR domain
suggests a role in steroid metabolism, as evidenced by up-
regulation of in vitro expression ofWWOX by sex steroids,
as well as the observation of impaired in vivo steroidogen-
esis in the Wwox knockout mice.45 The highest normal
expression of WWOX has been observed in hormonally
regulated tissues, including testis, ovaries, and pros-
tate.46,47 Much of the previous literature implicates
WWOX in cancer biology.45 WWOX is located within
the second-most-active common fragile site, FRA16D,
and deletions or translocations of WWOX have been ob-
served inmany cancer types.48 Recently,Wwoxwas shown
to function as a tumor suppressor in mice heterozygous for
a targeted deletion of Wwox.47 In that study, the authors
suggested that the homozygous knockout mice that die
by 4 weeks of age might suffer from a severe metabolic de-
fect: They observed dramatic changes in the serum levels of
lipids, carbohydrates, and proteins in these mice and, al-
though they performed a thorough histological survey of
the major organs, they could not identify any lesions
that could have accounted for the premature death.47
However, the underlying mechanism(s) by which
WWOX inﬂuences HDL-C levels is currently unknown,
and further studies are warranted to elucidate these molec-
ular mechanisms.
In conclusion, we have identiﬁed, within the WWOX
gene on chromosome 16q23–q24, a variant that is signiﬁ-
cantly associated with HDL-C levels in dyslipidemic fa-
milies and low-HDL-C cases and controls, as well as in
population-based cross-sectional and prospective cohorts.
We also demonstrate that the variant, rs2548861, appears
to reside in a functional cis-regulatory element that forms
a DNA-nuclear factor complex and that there is a signiﬁ-
cant allelic effect of rs2548861 on the regulatory function.
Taken together, these genetic and functional data identify
an HDL-C-associated WWOX variant with an allele-spe-
ciﬁc cis-regulatory function.
Supplemental Data
Four ﬁgures and two tables are available with this article online at
http://www.ajhg.org/.
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